An appeals court has said that while it might be desirable for law firms to disclose their involvement in drafting expert reports, they are not legally obligated to do so, overturning a finding that Corrs Chambers Westgarth went “far beyond the permissible scope” of involvement in a report prepared for a trade secrets case.
American fast food chain In-N-Out Burgers has won an injunction against a Queensland ‘ghost kitchen’ that operates solely through meal delivery apps, after it failed to comply with court-ordered undertakings.
Israeli drug company Neurim Pharmaceuticals has lost a bid to patent a mini version of its melatonin tablet Circadin for children, after a successful challenge by Australian drug maker Generic Partners.
A client of Corrs Chambers Westgarth has filed an appeal after a judge found the firm went “far beyond the permissible scope” of involvement in an expert report prepared for a trade secrets case.
The conduct of Corrs Chambers Westgarth in the preparation of an ostensibly independent expert report in a trade secrets case “must not be repeated”, a judge has said, throwing out the expert’s evidence as potentially tainted by the law firm’s involvement.
The High Court has rejected plumbing company Repipe’s application to hear its case centred on the question of patent eligibility for computer-implemented inventions, saying the case was not an appropriate vehicle for special leave.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a “commercial outcome for a patentee”.
American fast food chain In-N-Out Burgers has settled a trade mark dispute with a Queensland fast food business that operates “ghost kitchens” under the name In & Out Aussie Burgers.
Melbourne craft beer producer Brick Lane Brewing Co has filed proceedings accusing three companies behind the zero carb Better Beer of ripping off its packaging in breach of the Australian Consumer Law.
Merck Sharp & Dohme is seeking to overturn a judgment refusing an extension of a patent covering its Januvia and Janumet diabetes drugs that would have seen the US drug maker of retaining a monopoly over the multibillion dollar medicines beyond July 2022.